The accuracy of warfarin dosage based on VKORC1 and CYP2C9 phenotypes in a Chinese population

被引：0
|
作者：
Wijaya, Agustinus [1 ]
Bo, Jiang T. [1 ]
Jun, He [2 ]
Ping, Jiang W. [1 ]
Bin, Jiang [1 ]
Jie, Chen H. [2 ]
Wen, Yang B. [1 ]
Zhu, Xu M. [1 ]
Cheng, Qiu Q. [2 ]
机构：
[1] Soochow Univ, Affiliated Hosp 1, Dept Cardiovasc Dis, Suzhou, Jiangsu, Peoples R China
[2] Soochow Univ, Affiliated Hosp 1, Dept Haematol, Suzhou, Jiangsu, Peoples R China
来源：
MEDICAL JOURNAL OF INDONESIA | 2012年 / 21卷 / 02期
关键词：
CYP2C9; pharmacogenetic algorithm; VKORC1; warfarin;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Background: The aim of this study is to assess the accuracy of warfarin dosage based on VKORC1 and CYP2C9 genotype in Chinese population. Methods: Blood samples were taken from 37 patients. We compared the warfarin dosage obtained from genotype ( according to www. warfarindosing. org) and treatment dosage with international normalized ratio (INR) value within 2.0-3.0. Results: The majority of Chinese people in our study are VKORC1 homozygous AA (89.2%), rarely VKORC1 heterozygous AG and we cannot find a patient with homozygous GG. For CYP2C9 genotype, most patients have the wildtype variants (CYP2C9*2 CC and CYP2C9*3 AA). The warfarin dosage for patients with VKORC1 AA and CYP2C9*3 AC is lower than for patients with other genotype variants. Conclusion: There is no significant difference between pharmacogenetic algorithm (www. warfarindosing. org) and our treatment dosage. Our conclusion is that the pharmacogenetic algorithm is accurate to predict the warfarin dose.
引用
收藏
页码：108 / 112
页数：5
相关论文
共 50 条
  • [41] Pharmacokinetic and Pharmacodynamic Variation Associated with VKORC1 and CYP2C9 Polymorphisms in Thai Patients Taking Warfarin
    Sangviroon, Alisara
    Panomvana, Duangchit
    Tassaneeyakul, Wichittra
    Namchaisiri, Jule
    DRUG METABOLISM AND PHARMACOKINETICS, 2010, 25 (06) : 531 - 538
  • [42] PREVALENCE OF COMBINATORIAL CYP2C9 AND VKORC1 GENOTYPES IN PUERTO RICANS: IMPLICATIONS FOR WARFARIN MANAGEMENT IN HISPANICS
    Duconge, Jorge
    Cadilla, Carmen L.
    Windemuth, Andreas
    Kocherla, Mohan
    Gorowski, Krystyna
    Seip, Richard L.
    Bogaard, Kali
    Renta, Jessica Y.
    Piovanetti, Paola
    D'Agostino, Darrin
    Santiago-Borrero, Pedro J.
    Ruano, Gualberto
    ETHNICITY & DISEASE, 2009, 19 (04) : 390 - 395
  • [43] Prediction of the impact of CYP2C9 and VKORC1 genotypes on warfarin-sorafenib interactions in whites and Asians
    Asari, Kazuhiko
    Takahashi, Harumi
    PHARMACOGENOMICS, 2020, 21 (12) : 853 - 862
  • [44] Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy
    Ferder, N. S.
    Eby, C. S.
    Deych, E.
    Harris, J. K.
    Ridker, P. M.
    Milligan, P. E.
    Goldhaber, S. Z.
    King, C. R.
    Giri, T.
    McLeod, H. L.
    Glynn, R. J.
    Gage, B. F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (01) : 95 - 100
  • [45] The influence of VKORC1 and CYP2C9 mutations on warfarin response after total hip and knee arthroplasty
    Wise, Eric S.
    Gadomski, Stephen P., II
    McMaster, William G., Jr.
    Wilson, Robert J.
    Nelms, Justin K.
    Hocking, Kyle M.
    Brophy, Colleen M.
    JOURNAL OF ORTHOPAEDICS, 2015, 12 : S145 - S151
  • [46] Association between polymorphisms of the VKORC1 and CYP2C9 genes and warfarin maintenance dose in Peruvian patients
    Oscanoa, Teodoro J.
    Guevara-Fujita, Maria L.
    Fujita, Ricardo M.
    Munoz-Paredes, Maria Y.
    Acosta, Oscar
    Romero-Ortuno, Roman
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (03) : 769 - 775
  • [47] Genetic polymorphisms of VKORC1, CYP2C9, CYP4F2 in Bai, Tibetan Chinese
    Zeng, W. T.
    Zheng, Q. S.
    Huang, M.
    Cen, H. J.
    Lai, Y.
    Chen, W. Y.
    Zhao, L. Z.
    Leng, X. Y.
    PHARMAZIE, 2012, 67 (01): : 69 - 73
  • [48] Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy
    Al-Eitan, Laith N.
    Almasri, Ayah Y.
    Khasawneh, Rame H.
    SAUDI PHARMACEUTICAL JOURNAL, 2019, 27 (04) : 484 - 490
  • [49] The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment
    Skov, Jane
    Bladbjerg, Else-Marie
    Leppin, Anja
    Jespersen, Jorgen
    THROMBOSIS RESEARCH, 2013, 131 (02) : 125 - 129
  • [50] The effects of CYP2C9 and VKORC1 gene polymorphisms on warfarin maintenance dose in Turkish cardiac patients
    Akdeniz, Cansu Selcan
    Cevik, Mehtap
    Canbolat, Ismail Polat
    Yurdakul, Selen
    Cagatay, Penbe
    Ciftci, Cavlan
    Karaalp, Atila
    Susleyici, Belgin
    FUTURE CARDIOLOGY, 2020, 16 (06) : 645 - 654
12345